표준 치료를 받고 있는 제2형 당뇨병 환자에서 오령산 병용 투여의 후향적 약물 상호작용 연구 (A Retrospective Herb-Drug Interaction Study of Oryeong-san (Wuling-san) Co-administration in Type 2 Diabetes Patients Receiving Hypoglycemic Treatment)

서지정보

· 발행기관 : 대한한방내과학회
· 수록지 정보 : 대한한방내과학회지 / 45권 / 4호 / 602 ~ 614페이지
· 저자명 : 송미령, 정우녕, 유연주, 이민승, 안영민, 안세영, 이병철

초록

Objectives: This study investigated the effects of Korean medicine Oryeong-san (五苓散) on blood glucose levels and evaluated its safety in patients with type 2 diabetes.
Methods: A total of 87 patients aged 19 years and older, hospitalized for at least three days at the Kyung Hee University Korean Medical Hospital from January 1, 2021, to December 31, 2023 and continuously consumed Oryeong-san for a minimum of three days, were included. Their clinical characteristics and laboratory tests were reviewed retrospectively. The effects of Oryeong-san on fasting (FBS) and 2-hour postprandial (PP2) blood glucose were assessed by comparing the averages of measurements taken before and after the treatment. To evaluate the safety of the herbal extract, liver function test and kidney function test results were compared, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine (Cr), and estimated glomerular filtration rate (eGFR).
Results: The average duration of Oryeong-san consumption was 17.71±26.82 days. Although the FBS decreased and the PP2 slightly increased, these changes were not statistically significant (p>0.05). Safety assessments showed that the average levels of AST decreased, while the level of ALT increased, without statistical significance. The BUN levels also significantly decreased, while Cr and eGFR levels remained stable.
Conclusion: This study indicates that Oryeong-san is safe for use in type 2 diabetes patients without significant impact on blood glucose and that it has a positive safety profile.

영어초록

Objectives: This study investigated the effects of Korean medicine Oryeong-san (五苓散) on blood glucose levels and evaluated its safety in patients with type 2 diabetes.
Methods: A total of 87 patients aged 19 years and older, hospitalized for at least three days at the Kyung Hee University Korean Medical Hospital from January 1, 2021, to December 31, 2023 and continuously consumed Oryeong-san for a minimum of three days, were included. Their clinical characteristics and laboratory tests were reviewed retrospectively. The effects of Oryeong-san on fasting (FBS) and 2-hour postprandial (PP2) blood glucose were assessed by comparing the averages of measurements taken before and after the treatment. To evaluate the safety of the herbal extract, liver function test and kidney function test results were compared, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine (Cr), and estimated glomerular filtration rate (eGFR).
Results: The average duration of Oryeong-san consumption was 17.71±26.82 days. Although the FBS decreased and the PP2 slightly increased, these changes were not statistically significant (p>0.05). Safety assessments showed that the average levels of AST decreased, while the level of ALT increased, without statistical significance. The BUN levels also significantly decreased, while Cr and eGFR levels remained stable.
Conclusion: This study indicates that Oryeong-san is safe for use in type 2 diabetes patients without significant impact on blood glucose and that it has a positive safety profile.

참고자료

· 없음